Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter Summaries of opinion (16) Apply Summaries of opinion filter Withdrawn applications (14) Apply Withdrawn applications filter Paediatric investigation plans (174) Apply Paediatric investigation plans filter Orphan designations (117) Apply Orphan designations filter Direct healthcare professional communication (11) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (6) Apply Yes filter

Authorisation status

Authorised (342) Apply Authorised filter Refused (1) Apply Refused filter Withdrawn (38) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Referral name

Referral status

European Commission final decision (17) Apply European Commission final decision filter

Referral safety status

Yes (6) Apply Yes filter

Referral type

Article 20 procedures (12) Apply Article 20 procedures filter Article 31 referrals (5) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (15) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (12) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (12) Apply Risk minimisation measures filter Suspension (2) Apply Suspension filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Decision date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Conditional approval Remove Conditional approval filter Biosimilar (76) Apply Biosimilar filter Exceptional circumstances (39) Apply Exceptional circumstances filter Generic (256) Apply Generic filter Orphan medicine (135) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

398 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter

Categories Human Remove Human filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Conditional approval Remove Conditional approval filter

Sort by

List item

Human medicine European public assessment report (EPAR): Tecentriq (updated)

atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung, Urologic Neoplasms, Breast Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 20/09/2017, , Revision: 13, Authorised, Last updated: 05/03/2021
List item

Human medicine European public assessment report (EPAR): Comirnaty (updated)

Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020, , , Revision: 3, Authorised, Last updated: 04/03/2021
List item

Human medicine European public assessment report (EPAR): COVID-19 Vaccine Moderna (updated)

CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021, , , Authorised, Last updated: 04/03/2021
List item

Human medicine European public assessment report (EPAR): Ninlaro (updated)

ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016, , , , Revision: 9, Authorised, Last updated: 03/03/2021
List item

Human medicine European public assessment report (EPAR): Maviret (updated)

glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017, , , Revision: 11, Authorised, Last updated: 03/03/2021
List item

Human medicine European public assessment report (EPAR): Vyndaqel (updated)

tafamidis, Amyloidosis
Date of authorisation: 16/11/2011, , , , Revision: 18, Authorised, Last updated: 02/03/2021
List item

Human medicine European public assessment report (EPAR): Flixabi (updated)

infliximab, Spondylitis, Ankylosing, Arthritis, Rheumatoid, Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Psoriasis
Date of authorisation: 26/05/2016, , , Revision: 16, Authorised, Last updated: 01/03/2021
List item

Human medicine European public assessment report (EPAR): Herzuma (updated)

trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 08/02/2018, , , Revision: 11, Authorised, Last updated: 01/03/2021
List item

Human medicine European public assessment report (EPAR): Braftovi (updated)

Encorafenib, Melanoma, Colorectal Neoplasms
Date of authorisation: 19/09/2018, , Revision: 5, Authorised, Last updated: 01/03/2021
List item

Human medicine European public assessment report (EPAR): Ondexxya (updated)

andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019, , , Revision: 8, Authorised, Last updated: 01/03/2021
List item

Human medicine European public assessment report (EPAR): Glivec (updated)

imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Gastrointestinal Stromal Tumors, Dermatofibrosarcoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome
Date of authorisation: 07/11/2001, , Revision: 40, Authorised, Last updated: 01/03/2021
List item

Human medicine European public assessment report (EPAR): Ilumetri (updated)

tildrakizumab, Psoriasis
Date of authorisation: 17/09/2018, , Revision: 3, Authorised, Last updated: 26/02/2021
List item

Human medicine European public assessment report (EPAR): Vpriv (updated)

velaglucerase alfa, Gaucher Disease
Date of authorisation: 26/08/2010, , , Revision: 14, Authorised, Last updated: 26/02/2021
List item

Human medicine European public assessment report (EPAR): Taltz (updated)

ixekizumab, Psoriasis
Date of authorisation: 25/04/2016, , Revision: 12, Authorised, Last updated: 26/02/2021
List item

Human medicine European public assessment report (EPAR): Ervebo (updated)

recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein, Hemorrhagic Fever, Ebola
Date of authorisation: 11/11/2019, , Revision: 4, Authorised, Last updated: 25/02/2021
List item

Human medicine European public assessment report (EPAR): Dectova (updated)

Zanamivir, Influenza, Human
Date of authorisation: 26/04/2019, , Revision: 2, Authorised, Last updated: 25/02/2021
List item

Human medicine European public assessment report (EPAR): Truberzi (updated)

eluxadoline, Irritable Bowel Syndrome, Diarrhea
Date of authorisation: 19/09/2016, , Revision: 6, Withdrawn, Last updated: 25/02/2021
List item

Human medicine European public assessment report (EPAR): Inhixa (updated)

enoxaparin sodium, Venous Thromboembolism
Date of authorisation: 15/09/2016, , , Revision: 17, Authorised, Last updated: 24/02/2021
List item

Human medicine European public assessment report (EPAR): Neparvis (updated)

sacubitril, valsartan, Heart Failure
Date of authorisation: 26/05/2016, , Revision: 11, Authorised, Last updated: 24/02/2021
List item

Human medicine European public assessment report (EPAR): Cinryze (updated)

C1 inhibitor (human), Angioedemas, Hereditary
Date of authorisation: 15/06/2011, , Revision: 19, Authorised, Last updated: 24/02/2021
List item

Human medicine European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta) (updated)

umeclidinium bromide, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 20/03/2017, , Revision: 9, Authorised, Last updated: 24/02/2021
List item

Human medicine European public assessment report (EPAR): Prepandrix (updated)

A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2), Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 14/05/2008, , Revision: 13, Withdrawn, Last updated: 23/02/2021
List item

Human medicine European public assessment report (EPAR): Galafold (updated)

migalastat hydrochloride, Fabry Disease
Date of authorisation: 25/05/2016, , , Revision: 11, Authorised, Last updated: 23/02/2021
List item

Human medicine European public assessment report (EPAR): Idelvion (updated)

albutrepenonacog alfa, Hemophilia B
Date of authorisation: 11/05/2016, , , Revision: 9, Authorised, Last updated: 23/02/2021
List item

Human medicine European public assessment report (EPAR): Nepexto (updated)

etanercept, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Arthritis, Psoriatic, Spondylarthropathies, Spondylitis, Ankylosing, Psoriasis
Date of authorisation: 20/05/2020, , , Revision: 3, Authorised, Last updated: 22/02/2021